This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
SPRAVATO® (esketamine)
Medical Information
Use of SPRAVATO in Patients with Comorbid Parkinson’s Disease
Last Updated: 11/17/2025
SUMMARY
- SPRAVATO is not indicated for the treatment of Parkinson’s disease.
- Clinical studies designed to evaluate the efficacy and/or safety of SPRAVATO in patients with Parkinson’s disease have not been performed.
Literature Search
A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, DERWENT® (and/or other resources, including internal/external databases) conducted on 04 November 2025 did not identify any relevant citations pertaining to this topic.
Would you like to clear and leave your conversation? Message history will be lost.